AD/PD appoints FINN Partners as global PR agency

The conference focuses on research and treatment strategies for Alzheimer’s disease, Parkinson’s disease and related neurodegenerative disorders.

AD/PD has appointed FINN Partners as its global public relations agency of record, tasking the agency with raising the conference’s international profile and supporting participation across its scientific and clinical communities.

The partnership comes ahead of AD/PD 2027, which will take place from 16 to 20 March 2027 in Barcelona, Spain, and online as a hybrid event.

FINN Partners to lead AD/PD global communications

Dr. Abraham Fisher, co-founder and president, AD/PD: “What sets AD/PD™ apart is our comprehensive focus across the spectrum of neurodegenerative diseases and our commitment to bringing together scientists, clinicians, and industry leaders to translate research into real-world care. As we prepare for AD/PD™ 2027 in Barcelona, partnering with FINN allows us to amplify our message, reach a broader global audience, and accelerate scientific collaboration that ultimately leads to life-changing diagnostics and therapies for patients worldwide.”

FINN Partners’ Global Health Practice will lead media relations and stakeholder engagement. Its remit includes expanding the conference’s international footprint, strengthening participation among clinical and scientific communities and positioning AD/PD as a venue for translational neuroscience.

Agency to expand reach of neurodegenerative research

Richard Hatzfeld, senior partner and Brain Health Lead, FINN Partners: “Brain health is one of the most critical and rapidly evolving domains in medicine today, affecting millions of families worldwide. AD/PD™ has long been the epicenter for scientific discovery in Alzheimer’s, Parkinson’s, and related conditions. We are honored to serve as their strategic PR partner, mobilizing our ‘One FINN’ collaborative model across our Health Practice to elevate AD/PD™’s mission and accelerate the impact of groundbreaking science on a global scale.”

FINN Partners operates across 38 offices and has experience in global health communications, brain health and neurodegenerative science. The agency will support AD/PD in encouraging international abstract submissions and delegate participation, while promoting research across the conference’s 12 scientific tracks and communicating developments before and during the 2027 event.

AD/PD 2027 campaign targets global scientific audience

Ellie Hanson, senior partner and co-lead, FINN Partners Israel: “Many of our biotech, pharma, and health tech clients participated in and presented groundbreaking research at AD/PD™ through the years, making this partnership a natural extension of our work in the neurodegenerative space. We are thrilled to work alongside the AD/PD™ leadership team to elevate their international profile, increase delegate and speaker engagement, and champion the scientists and innovators working diligently to solve complex brain health challenges.”

adpd.kenes.com

www.finnpartners.com

Follow Marketing Report on LinkedIn